S Nylander

Summary

Affiliation: AstraZeneca R and D

Publications

  1. doi request reprint Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor
    S Nylander
    Department of Bioscience, AstraZeneca R and D Molndal, Molndal, Sweden
    J Thromb Haemost 10:2127-36. 2012
  2. ncbi request reprint Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action
    Sven Nylander
    Cell Biology and Biochemistry, Preclinical R and D, AstraZeneca R and D Molndal, Sweden
    Blood Coagul Fibrinolysis 14:159-67. 2003
  3. ncbi request reprint The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation
    Sven Nylander
    Preclinical R and D, Department of Molecular Pharmacology, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Thromb Res 111:65-73. 2003
  4. pmc Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation
    Sven Nylander
    Department of Molecular Pharmacology, Preclinical R and D, AstraZeneca R and D, Molndal, Sweden
    Br J Pharmacol 142:1325-31. 2004
  5. ncbi request reprint Characterisation of species differences in the platelet ADP and thrombin response
    Sven Nylander
    Department of Molecular Pharmacology, Preclinical R and D, AstraZeneca R and D, Molndal, 431 83 Mölndal, Sweden
    Thromb Res 117:543-9. 2006
  6. ncbi request reprint Evaluation of platelet function, a method comparison
    S Nylander
    Department of Molecular Pharmacology, Preclinical R and D, AstraZeneca R and D, Molndal, Sweden
    Platelets 17:49-55. 2006
  7. ncbi request reprint Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro
    C Mattsson
    AstraZeneca R and D, Cell Biology and Biochemistry, , Sweden
    Thromb Res 104:475-86. 2001
  8. ncbi request reprint Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism
    S Nylander
    AstraZeneca R and D, Molndal, Sweden
    J Thromb Haemost 11:1867-76. 2013
  9. ncbi request reprint Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry
    S Nylander
    Cell Biology and Biochemistry, Preclinical R and D, ASTRA Hässle, Molndal, Sweden
    J Immunol Methods 224:69-76. 1999

Detail Information

Publications9

  1. doi request reprint Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor
    S Nylander
    Department of Bioscience, AstraZeneca R and D Molndal, Molndal, Sweden
    J Thromb Haemost 10:2127-36. 2012
    ..Based on in vitro and animal data, PI3Kβ is given an important role in platelet adhesion and aggregation but its role in insulin signaling is unclear...
  2. ncbi request reprint Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action
    Sven Nylander
    Cell Biology and Biochemistry, Preclinical R and D, AstraZeneca R and D Molndal, Sweden
    Blood Coagul Fibrinolysis 14:159-67. 2003
    ..Thus, reversible direct thrombin inhibitors, such as melagatran, are potent inhibitors of thrombin-induced platelet activation, acting mainly by inhibition of a PAR-1-independent component...
  3. ncbi request reprint The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation
    Sven Nylander
    Preclinical R and D, Department of Molecular Pharmacology, AstraZeneca R and D Molndal, S 431 83 Molndal, Sweden
    Thromb Res 111:65-73. 2003
    ..Above this concentration, the relative importance of P2Y(12) inhibition decreased due to activation of ADP independent pathways. This study supports P2Y(12) as a drug target compared with P2Y(1)...
  4. pmc Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation
    Sven Nylander
    Department of Molecular Pharmacology, Preclinical R and D, AstraZeneca R and D, Molndal, Sweden
    Br J Pharmacol 142:1325-31. 2004
    ..Whether this synergistic effect in vitro also results in an improved antithrombotic effect in vivo with or without an increased risk of bleeding remains to be studied in well-conducted clinical studies...
  5. ncbi request reprint Characterisation of species differences in the platelet ADP and thrombin response
    Sven Nylander
    Department of Molecular Pharmacology, Preclinical R and D, AstraZeneca R and D, Molndal, 431 83 Mölndal, Sweden
    Thromb Res 117:543-9. 2006
    ..A number of animal models are used to study platelet-dependent diseases. In the present investigation, we have used a simple flow cytometry assay to evaluate platelet function in man, rat, mouse, guinea pig and dog...
  6. ncbi request reprint Evaluation of platelet function, a method comparison
    S Nylander
    Department of Molecular Pharmacology, Preclinical R and D, AstraZeneca R and D, Molndal, Sweden
    Platelets 17:49-55. 2006
    ..The two studied assays compare well with the more established assays, and are thus both good alternatives for platelet function testing and evaluation of new potential platelet antagonists...
  7. ncbi request reprint Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro
    C Mattsson
    AstraZeneca R and D, Cell Biology and Biochemistry, , Sweden
    Thromb Res 104:475-86. 2001
    ..Whether this will influence their clinical efficacy or safety versus heparin and warfarin, which also inhibit protein activation, respectively, lowers the concentration of protein C, remains to be studied in clinical trials...
  8. ncbi request reprint Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism
    S Nylander
    AstraZeneca R and D, Molndal, Sweden
    J Thromb Haemost 11:1867-76. 2013
    ..Ticagrelor, a P2Y12 antagonist, is an antiplatelet agent approved for the treatment of acute coronary syndromes; it also inhibits adenosine uptake by erythrocytes and other cells...
  9. ncbi request reprint Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry
    S Nylander
    Cell Biology and Biochemistry, Preclinical R and D, ASTRA Hässle, Molndal, Sweden
    J Immunol Methods 224:69-76. 1999
    ....